This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: The antiparkinsonian drug l-dopa causes increased cellular synthesis of homocysteine and consequent hyperhomocysteinemia in rats. This effect of l-dopa on plasma homocysteine is accentuated under conditions of impaired homocysteine metabolism such as folate deficiency.
Objective: To investigate the effect of l-dopa administration and B-vitamin status on plasma homocysteine concentrations in humans with PD.
Methods: Plasma homocysteine, folate, vitamin B12, and pyridoxal-5′-phosphate (PLP) concentrations were determined in 40 individuals diagnosed with idiopathic PD who were being treated as outpatients at the Boston University Medical Center Neurology Clinic. Twenty of the patients were on l-dopa therapy (treatment group) and 20 were l-dopa-naive (control group).
Results: The mean plasma homocysteine concentration was higher in the treatment group than in the controls (p = 0.018). Plasma homocysteine was correlated with plasma folate, vitamin B12, and PLP concentrations in the treatment group (p ≤ 0.007) but not in the controls.
Conclusion: l-Dopa can cause hyperhomocysteinemia in PD patients, the extent of which is influenced by B-vitamin status. The B-vitamin requirements necessary to maintain normal plasma homocysteine concentrations are higher in l-dopa-treated patients than in those not on l-dopa therapy. B-Vitamin supplements may be warranted for PD patients on l-dopa therapy.
- Received September 19, 2002.
- Accepted December 28, 2002.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
- Reply to Both Letters to the Editor
- Effect of L-dopa on plasma homocysteine in PD patients: Relationship to B-vitamin status
- Effect of L-dopa on plasma homocysteine in PD patients: Relationship to B-vitamin status
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD
Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease
Hyperhomocysteinemia as an independent risk factor for silent brain infarction
Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease